Physician profile
Dawn E Ebersole
NPI 1841732617
$4,715.26
in general payments reported to CMS, 2019-2025
20 companies · $1,213 in 2025
The $1,213 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $113 · 2022: $757 · 2023: $1,411 · 2024: $1,221 · 2025: $1,213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,804 · Education: $41.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,803.78 |
| Education | $41.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,048.60 | 2021-2025 | |
| Intercept Pharmaceuticals, INC. | $553.58 | 2022-2025 | Ocaliva |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $424.51 | 2022-2024 | Xifaxan |
| Gilead Sciences, INC. | $407.96 | 2023-2025 | Epclusa, Livdelzi |
| Takeda Pharmaceuticals U.S.A., INC. | $400.86 | 2022-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $370.58 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $285.50 | 2024-2025 | Iqirvo, Bylvay |
| Janssen Biotech, INC. | $278.66 | 2022-2024 | Stelara, Remicade, Simponi |
| Janssen Scientific Affairs, LLC | $185.57 | 2024-2025 | Tremfya, Stelara |
| Ardelyx, INC. | $123.50 | 2025 | Ibsrela |
| Organon LLC | $115.98 | 2023-2025 | Renflexis, Hadlima |
| Aimmune Therapeutics, INC. | $103.59 | 2025 | Zenpep |
| Madrigal Pharmaceuticals | $91.74 | 2025 | Rezdiffra |
| Nestle Healthcare Nutrition INC. | $74.86 | 2022-2023 | |
| Alnylam Pharmaceuticals INC. | $54.79 | 2023 | Givlaari |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $48.95 | 2023-2024 | Injectafer |
| Amgen INC. | $48.39 | 2022-2023 | Amjevita |
| Pfizer INC. | $43.72 | 2023 | |
| Merck Sharp & Dohme LLC | $34.27 | 2022-2023 | Dificid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.65 | 2024 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Ebersole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.